Navigation Links
Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausibly confounded by survival benefit of post-study treatment with ERBITUX -

NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced detailed results from the EPIC study - a randomized, open-label, multi-center Phase III trial - comparing ERBITUX(R) (Cetuximab) plus irinotecan to irinotecan alone in patients with metastatic colorectal cancer (mCRC) who failed first-line therapy. Results showed that the secondary endpoints of progression-free survival and response rate were significantly higher in the ERBITUX-irinotecan arm. The median time of survival without disease progression was improved by 54% in the patients who received ERBITUX plus irinotecan. This benefit produced a significant 31% reduction in the risk of disease progression (Hazard ratio, 0.692; 95% CI = 0.617- 0.776; p<0.0001). Additionally, patients in the ERBITUX-irinotecan arm were four times more likely to experience a 50% reduction in tumor size over patients treated with irinotecan alone (p<0.0001).

"The improvement in progression-free survival and response rate expands our understanding of the significant activity of ERBITUX," said Eric Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We believe these outcomes add to the existing clinical evidence demonstrating the safety and effectiveness of ERBITUX in combination with chemotherapy."

As previously reported, the study's primary endpoint of overall survival was not different between the two groups (Hazard ratio, 0.975; 95.03% CI = 0.854 - 1.114; p=0.7115). Analysis of the data show that a considerable number of patients randomized to the irinotecan arm went on to receive ERBITUX with or without irinotecan after failing irinotecan alone. Extensive post-trial use of ERBITUX may explain the lack of difference in overall
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician associations ... doctors the survival tools they need to provide demonstrably ... today,s health care marketplace. "I am confident ... local practices," said Stephen L. Brotherton ... " Texas doctors are determined to ...
(Date:5/23/2013)... 2013   Direct to implant, or "one ... appropriate option for many women with BRCA (BReast ... breast cancer risk, or with breast cancer. Traditionally, ... a second surgery to insert permanent implants, but ... as mastectomy can be a medically and cosmetically ...
(Date:5/23/2013)... May 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), ... comments on the FDA panel meeting for non-thermal shortwave ... – Pulsed Shortwave Therapy Meeting was held on May ... USA.  The focus of the meeting was very narrow, ... focus solely on the application of non-thermal shortwave diathermy ...
Breaking Medicine Technology:TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... 2 STAAR Surgical Company (Nasdaq: STAA ), ... ophthalmic products, today reported that it generated $464,000 in ... The cash generated was the largest amount from operating ... years. This achievement was made possible due ...
... , HOPKINTON, Mass., Nov. 2 Caliper Life Sciences, Inc. ... tools, presented at a training session for reviewers from the ... of the LabChip GX platform for high throughput screening and ... accept the FDA,s invitation to present our LabChip platform to ...
Cached Medicine Technology:STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 2STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 3STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 4STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 5STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 6STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 7STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 8STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 9STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 10STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 11STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 12STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 13STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 14STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 15STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 16STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 17STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 18STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 19STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 20STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 21STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 22STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 23STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter 24Caliper Life Sciences Presents LabChip(R) Platform to the U.S. Food and Drug Administration 2
(Date:5/24/2013)... Bridal Buy , a leading wedding dress online ... dresses are available in its wedding dresses 2013 ... fine fabrics, elegant beading, and exquisite embroidery. , ... eye for detailed designs. However, our lace spring wedding ... patterns and the hands of dressmakers,” said, Donnie Terry, ...
(Date:5/24/2013)... 2013 Psoriasis treatment cream has been ... This new FDA registered company is now offering its ... appearance of Psoriasis infected skin. , Dermasis has launched ... online. This soothing cream is designed to offer immediate ... and appearance of red skin often caused by psoriasis ...
(Date:5/23/2013)... blood glucose is associated with poor outcomes in hospitalized ... control hyperglycemia is a common practice in hospitals. But ... and even shows harms associated with the use of ... Clinical Guidelines Committee in a new evidence-based paper published ... Quality . , "Clinicians caring for hospitalized patients must ...
(Date:5/23/2013)... 24, 2013 On March 14, 2012, Kim ... will hear in her lifetime: she had breast cancer. Her ... After a Breast Cancer Diagnosis ” (published by AuthorHouse), takes ... Rideout drew from her daily journals to give readers a ... chemotherapy and radiation treatments to deal with stage two breast ...
(Date:5/23/2013)... May 23, 2013 If you are ... irritable bowel syndrome (IBS), the food spread this Memorial ... fun. , “While hot dogs and ice cream have ... warm weather months, IBS sufferers often feel the painful ... MD, a gastroenterologist with Lourdes Medical Associates. , IBS ...
Breaking Medicine News(10 mins):Health News:Dermasis Psoriasis Treatment Cream for Men and Women Released Online at HealthCareSupplementz.com 2Health News:ACP issues recommendations for management of high blood glucose in hospitalized patients 2Health News:Kimberley Rideout Shares Her Triumphant Cancer Survival Story 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 2Health News:Sensitive Stomach? Lourdes Gastroenterologist Advises IBS Sufferers to Think Twice About What They Eat This Holiday Weekend 3
... VSCP ), a leading provider of quantitative ... the company,s chief executive,officer, will be presenting a corporate ... Conference at the Waldorf Astoria in New York City. ... at 3:45pm EST. , A ...
... finds all breaks, not just hip fractures, tied to increased ... fracture that occurs in people over age 60 needs to ... the Australian researchers found the risk of dying goes up ... for at least 10 years after a hip fracture. , ...
... former Senator Tom Daschle withdrew his name for consideration ... Human Services Department (HHS). From the beginning Senator ... for President Obama for a government takeover of our ... record while in the Senate, Family Research Council has ...
... Nearly three out of four Americans (71 ... cost of addiction treatment - yet most consumers ... would pay for substance abuse treatment, according to ... Hazelden, the national nonprofit organization that helps people ...
... until third year, study finds , , TUESDAY, Feb. ... period" for hormone replacement therapy has been identified ... that using estrogen-plus-progesterone therapy increases the risk for ... than taking estrogen alone. , The finding follows ...
... One-fifth of women who should receive radiation after a ... to a new study from researchers at the University ... at 396 women who were treated with a mastectomy ... of women who fell clearly within guidelines recommending radiation ...
Cached Medicine News:Health News:VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference 2Health News:Fractures in Older Adults Up Death Risk 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4Health News:2 Years of Hormone Use May Be 'Safe' 2Health News:19 percent of breast cancer patients don’t receive recommended radiation after mastectomy 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: